| Literature DB >> 15488139 |
Giorgio Coen1, Eleonora Moscaritolo, Carlo Catalano, Raffaella Lavini, Italo Nofroni, Giuseppe Ronga, Daniela Sardella, Alvaro Zaccaria, Rosario Cianci.
Abstract
BACKGROUND: Renal artery stenosis (RAS) is a known cause of hypertension and ischemic nephropathy. Stenting of the artery is a valid approach, in spite of cases of unexpected adverse evolution of renal function.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15488139 PMCID: PMC527878 DOI: 10.1186/1471-2369-5-15
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Clinical and biochemical data of the stented and control groups
| Stented | Control | ||||
| 27 | 19 | ||||
| 67,3 ± 6,8 | 70.0 ± 6,1 | n.s | |||
| 17/10 | 15/4 | n.s. | |||
| 169,1 ± 23 | 165,8 ± 24,7 | n.s. | |||
| 89,1 ± 14,8 | 87,4 ± 13,4 | n.s. | |||
| 2,15 ± 0,9 | 1,99 ± 0,7 | n.s. | |||
| 36,1 ± 17,3 | 34,6 ± 15,6 | n.s. | |||
| 73,2 ± 36,7 | 75,5 ± 29,2 | n.s. | |||
| 236,9 ± 33,8 | 241,1 ± 41,2 | n.s. | |||
| 181,2 ± 87,6 | 166,1 ± 82,8 | n.s. | |||
| 139,7 ± 5,2 | 142,0 ± 3,3 | n.s. | |||
| 4,34 ± 0,5 | 4,7 ± 0,6 | n.s. | |||
| 308 ± 323 | 545 ± 572 | n.s. | |||
| 6,8 ± 1,4 | 6,6 ± 2,3 | n.s. | |||
| 0,76± 0,11 | (25) | 0,79± 0,04 | n.s. | ||
| 78,8 ± 8,66 | (25) | 79,06 ± 9,0 | n.s. | ||
| % | % | ||||
| 14/27 | 51,9 | 12/19 | 63,2 | n.s. | |
| 25/27 | 92,6 | 19/19 | 100 | n.s. | |
| 8/27 | 29,6 | 9/19 | 47,4 | n.s. | |
| 17/27 | 63 | 15/19 | 78,9 | n.s. | |
| 17/27 | 63 | 13/19 | 76,5 | n.s. |
Timecourse of blood pressure (mm Hg), number of antihypertensive drugs and proteinuria (mg/24 h) in the stented and control groups
| 169 ± 23 | 89 ± 14,8 | 2,07 ± 1,1 | 309 ± 323 | |
| 155 ± 12,9* | 81,9 ± 6,77* | 1,93 ± 1,07 | 764 ± 690* | |
| 157 ± 17,7* | 82,0 ± 6,31* | 1,6 ± 1,05* | 1381 ± 2160 | |
| 148 ± 12,2* | 81,4 ± 5,39* | 1,42 ± 0,93* | 1743 ± 2884 | |
| 152 ± 14,4* | 81,2 ± 8,87* | 1,7 ± 1,17 | 1377 ± 1643* | |
| 165,8 ± 24,6 | 87,4 ± 13,4 | 2,37 ± 0,83 | 545 ± 572 | |
| 163,7 ± 16,5 | 83,0 ± 10,2 | 2,26 ± 0,93 | 534 ± 404 | |
| 155,6 ± 20,4 | 88,1 ± 8,45 | 1,82 ± 0,73 | 812 ± 536 | |
| 154,4 ± 20,8 | 87,1 ± 8,21 | 2,0 ± 0,94 | 225 ± 368 | |
(*) = Significant difference compared to basal value (p < 0,05)
Evolution of creatinine clearance (ml/min) and serum creatinine (mg/dl).
| 36,07 ± 17,2 (27) | 2,15 ± 0,94 | 34,78 ± 15,5 (19) | 1,99 ± 0,72 | |
| 35,29 ± 16,39 | 2,32 ± 1,33 | - | - | |
| 34,78 ± 14,38 | 2,18 ± 0,76 | 29,99 ± 12,4 | 2,13 ± 0,73 | |
| 37,03 ± 18,0 | 2,15 ± 0,94 | 33,84 ± 17,9 | 2,01± 0,66 | |
| 40,42 ± 21,63 (26) | 2,03 ± 0,73 | 34,78 ± 14,3 (14) | 1,98 ± 0,56 | |
Figure 1Evolution of percent GFR in the stented and controlateral kidneys.
Figure 2Timecourse of creatinine clearance in stented patients with Resistance index < and > of 0.80. Significance of the difference is indicated (*)
Figure 3Inverse correlation between Resistance index and changes in creatinine clearance after stenting